ThinkScopeThe Corona Remedies IPO is generating considerable buzz ahead of its listing on Monday, with its grey market premium experiencing a significant rise to Rs 330.
This increase reflects the growing optimism among investors regarding the company's future prospects and potential for growth.
The company's strong financial foundation and promising business model are key factors contributing to this positive sentiment.
As the listing date approaches, all eyes are on how the market will respond to Corona Remedies' debut, with many anticipating a successful start to its public trading journey, potentially setting the tone for future listings in the sector.
